Fentanyl iontophoretic - ALZA Corporation

Drug Profile

Fentanyl iontophoretic - ALZA Corporation

Alternative Names: E-TRANS fentanyl; Fentanyl iontophoretic transdermal system; Fentanyl transdermal - ALZA Corporation; IONSYS; SyB P 1501

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ALZA Corporation
  • Developer ALZA Corporation; SymBio Pharmaceuticals; The Medicines Company
  • Class General anaesthetics; Opioid analgesics; Piperidines; Small molecules
  • Mechanism of Action Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Postoperative pain

Most Recent Events

  • 01 Sep 2016 The Medicines Company completes a phase III trial for Postoperative pain (In adolescents) in USA (NCT02395653)
  • 13 Jun 2016 Phase-III clinical trials in Postoperative pain in Japan (Transdermal)
  • 20 Nov 2015 Registered for Postoperative pain in Norway, Iceland and Liechtenstein (Transdermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top